Cytrellis Biosystems is a Woburn, Mass.-based medical technology company focused on development and commercialization of aesthetic devices that emphasize safety, efficacy, and improved quality of life. Led by President and CEO Karen Cronholm, the company developed the ellacor™ System using Micro-Coring™ Technology to remove sagging skin associated with aging without surgery or scarring. Ellacor is indicated for treatment of moderate to severe wrinkles in the mid to lower face in adults aged 22 years or older with Fitzpatrick skin types I–IV. The device recently received FDA clearance, providing a pathway to an initial commercial rollout with a small group of key physicians and a planned full national rollout in 2022. Cytrellis closed a $50M Series C to build commercial infrastructure and to support additional clinical research, product development, and manufacturing. Cytrellis Biosystems is a Woburn, Mass.-based medical technology company developing a proprietary class of dermatologic aesthetic devices aimed at reducing skin laxity. Its core product line targets removal of sagging skin associated with aging without surgery or scarring. The company is led by President and CEO Karen Cronholm. Cytrellis recently completed a financing to support clinical and regulatory work. It intends to use the proceeds to conclude clinical studies and fund efforts to obtain regulatory clearances. The company’s development stage and regulatory focus suggest the capital will be deployed toward validation and market-enabling activities. Cytrellis is a clinical-stage Boston company developing an entirely new category of medical devices for the aesthetics market that remove excess skin without invasive surgery or scarring. Its key proprietary technology is intended to enable physicians to improve sagging skin on the face and other areas of the body. The company is positioning the product to address a large unmet need in aesthetic medicine and to capture a valuable market opportunity. Cytrellis has pursued a strategy of selectively engaging investors who provide specific aesthetics industry expertise. The company aims for a successful market launch of its technology once clinical development is complete. No operating metrics or financial details were disclosed in the article.

Total raised

$79M

Funding rounds

3

Latest round

Series C

Latest activity

Sep 2021